Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

O1‐02‐03: DIAN‐TU ADAPTIVE PREVENTION TRIAL LAUNCH AND BASELINE DATA
Santacruz, Anna , Farlow, Martin R. , Salloway, Stephen , Fagan, Anne M. , Wang, Guoqiao , Koeppe, Bob, Martényi, Ferenc, Yaari, R. , Siemers, Eric , Clifford, David B. , Bateman, Randall J. , Mills, Susan, Morris, John C. , Benzinger, Tammie L.S. , Goate, Alison , Hassenstab, Jason , Xiong, Chengjie , Jack, Clifford R. , Searle, Alison, McDade, Eric

Mayo Clinic

Alzheimer's & Dementia | October 22, 2018 | Volume: 14 | Issue: 7S_Part_3 | Pages: No page available

10.1016/j.jalz.2018.06.2338 Get It

IC‐P‐204: THE RELATIONSHIP BETWEEN TAU PET AND OTHER AD BIOMARKERS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE
Christensen, Jon, Dincer, Aylin , Keefe, Sarah , Wang, Guoqiao , Raichle, Marcus E. , Koeppe, Bob, Network, Dominantly Inherited Alzheimer's, Gordon, Brian A. , Blazey, Tyler , Flores, Shaney , McDade, Eric , Jack, Clifford R. , Morris, John C. , Bateman, Randall J. , Benzinger, Tammie L.S. , Network, Dominantly Inherited Alzheimer's

Mayo Clinic

Alzheimer's & Dementia | October 22, 2018 | Volume: 14 | Issue: 7S_Part_3 | Pages: No page available

10.1016/j.jalz.2018.06.2271 Get It

P3‐129: MAPPING FUNCTIONAL REGULATORY VARIANTS AT ALZHEIMER'S DISEASE RISK LOCI
Allen, Mariet , Bredenberg, Jenny M., Reddy, Joseph S. , Sarangi, Vivekananda , Carrasquillo, Minerva M. , Lincoln, Sarah, Nguyen, Thuy , Malphrus, Kimberly G., Asmann, Yan W. , Ertekin‐Taner, Nilüfer , Carrasquillo, Minerva M. , Wang, Xue, Dickson, Dennis W.

Mayo Clinic

Alzheimer's & Dementia | October 22, 2018 | Volume: 14 | Issue: 7S_Part_21 | Pages: No page available

10.1016/j.jalz.2018.06.1486 Get It

A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limited‐stage small cell lung cancer in elderly patients versus younger patients
Stinchcombe, Thomas E. , Fan, Wen, Bogart, Jeff, Thomas, Charles R., Edelman, Martin J. , Horn, Leora , Cohen, Harvey Jay, Ganti, Apar Kishor , Pang, Herbert , Wang, Xiaofei , Schild, Steven E. , Ganti, Apar K , Vokes, Everett E. , Le, Quynh‐Thu , Komaki, Ritsuko

Mayo Clinic

Cancer | October 21, 2018 | Volume: 125 | Issue: 3 | Pages: 382-390

10.1002/cncr.31813 | PMID 30343497 Get It

Background Platinum and etoposide with thoracic radiation followed by prophylactic cranial irradiation constitute the standard treatment for limited‐stage small cell lung cancer (LS‐SCLC). Many patients with LS‐SCLC are elderly with comorbidities. Methods Individual patient data were collected from 11 phase 2 or 3 trials for LS‐SCLC conducted by the National Clinical Trials Network and activated from 1990 to 2010. The primary endpoint was overall survival (OS); the secondary endpoints were progression‐free survival (PFS), the rate of severe adverse events, and off‐treatment reasons. The outcomes were compared for patients 70 years old or older (elderly patients) and patients younger than 70 years (younger patients). Results Individual patient data from 1049 younger patients (81%) and 254 elderly patients (19%) were analyzed. In the multivariate model, elderly patients, in comparison with younger patients, had worse OS (hazard ratio [HR], 1.38; 95% confidence interval [CI], 1.18‐1.63; median OS for elderly patients, 17.8 months; OS for younger patients, 23.5 months) and worse PFS (HR, 1.19; 95% CI, 1.03‐1.39; median PFS for elderly patients, 10.6 months; median PFS for younger patients, 12.3 months). Elderly patients, in comparison with younger patients, experienced more grade 5 adverse events (8% vs 3%; P < .01) and more grade 3 or higher dyspnea (11% vs 7%; P = .03) but less grade 3 or higher esophagitis/dysphagia (14% vs 19%; P = .04) and less grade 3 or higher vomiting (11% vs 17%; P = .01). Elderly patients completed treatment less often, discontinued treatment because of adverse events and patient refusal more frequently, and died during treatment more frequently. Conclusions Elderly patients with LS‐SCLC have worse PFS and OS and more difficulty in tolerating therapy. Future trials should incorporate assessments of elderly patients, novel monitoring of adverse events, and more tolerable radiation and systemic therapies.
PANOPLY: Omics-Guided Drug Prioritization Method Tailored to an Individual Patient
Sinnwell, Jason P. , Yu, Jia , Vedell, Peter T. , Weinshilboum, Richard M. , Wang, Liewei , Goetz, Matthew P. , Thompson, Kevin J. , Ingle, James N. , Suman, Vera, Sinnwell, Jason P , Kalari, Krishna R. , Tang, Xiaojia , Carlson, Erin E. , Weinshilboum, Richard M. , Boughey, Judy C. , Goetz, Matthew P. , Suman, Vera J.

Mayo Clinic

JCO Clinical Cancer Informatics | October 15, 2018 | Volume: No volume available | Issue: 2 | Pages: 1-11

10.1200/cci.18.00012 | PMID 30652605 Get It

Purpose The majority of patients with cancer receive treatments that are minimally informed by omics data. We propose a precision medicine computational framework, PANOPLY (Precision Cancer Genomic Report: Single Sample Inventory), to identify and prioritize drug targets and cancer therapy regimens. Materials and Methods The PANOPLY approach integrates clinical data with germline and somatic features obtained from multiomics platforms and applies machine learning and network analysis approaches in the context of the individual patient and matched controls. The PANOPLY workflow uses the following four steps: selection of matched controls to the patient of interest; identification of patient-specific genomic events; identification of suitable drugs using the driver-gene network and random forest analyses; and provision of an integrated multiomics case report of the patient with prioritization of anticancer drugs. Results The PANOPLY workflow can be executed on a stand-alone virtual machine and is also available for download as an R package. We applied the method to an institutional breast cancer neoadjuvant chemotherapy study that collected clinical and genomic data as well as patient-derived xenografts to investigate the prioritization offered by PANOPLY. In a chemotherapy-resistant patient-derived xenograft model, we found that that the prioritized drug, olaparib, was more effective than placebo in treating the tumor ( P < .05). We also applied PANOPLY to in-house and publicly accessible multiomics tumor data sets with therapeutic response or survival data available. Conclusion PANOPLY shows promise as a means to prioritize drugs on the basis of clinical and multiomics data for an individual patient with cancer. Additional studies are needed to confirm this approach.
NucMap: a database of genome-wide nucleosome positioning map across species
Zhao, Yongbing , Wang, Jinyue , Zhang, Hao , Jiang, Meiye , Zhang, Zhewen , Bào, Yīmíng , Zhang, Zhang , Wu, Jiayan , Asmann, Yan W. , Li, Rujiao , Xiao, Jingfa , Fang, Liang , Liu, Yanxia , Wang, Qi , Zhao, Wenming

Mayo Clinic

Nucleic Acids Research | October 10, 2018 | Volume: 47 | Issue: D1 | Pages: D163-D169

10.1093/nar/gky980 | PMID 30335176 Get It

Recurrent Genomic Alterations in Soft Tissue Perineuriomas
Carter, Jodi M. , Wu, Yanhong , Blessing, Melissa M. , Folpe, Andrew L. , Thorland, Erik C., Spinner, Robert J. , Jentoft, Mark E. , Baheti, Saurabh , Niu, Zhiyv , Mauermann, Michelle L. , Mauermann, Michelle L , Niu, Zhiyv , Wang, Chen , Klein, Christopher J. , Carter, Jodi

Mayo Clinic

American Journal of Surgical Pathology | October 10, 2018 | Volume: 42 | Issue: 12 | Pages: 1708-1714

10.1097/pas.0000000000001169 | PMID 30303818 Get It

Perineuriomas are rare nerve sheath tumors, divided into intraneural and extraneural (soft tissue) types. Intraneural perineuriomas frequently contain TRAF7 mutations, and rarely, chr22q12 deletions. While chr22q losses can occur in soft tissue perineuriomas, comprehensive high-resolution molecular profiling has not been reported in these tumors and TRAF7 status is unknown. We used whole-exome sequencing and OncoScan single nucleotide polymorphism (SNP) array to evaluate 14 soft tissue perineuriomas. Thirteen cases showed 2 or more chromosomal abnormalities, composed primarily of large deletions. Recurrent chr22q deletions, containing the NF2 locus (n=6) and the previously unreported finding of chr17q deletions, with the NF1 locus (n=4) were frequent events and were mutually exclusive in all but1 case. In addition, 5 cases had varying chr2 deletions; and 4 cases had chr6 deletions. A chr10 deletion (previously reported in the sclerosing variant of soft tissue perineurioma) was observed in one case and another case had chr7 chromothripsis as the sole chromosomal abnormality. No TRAF7 mutations or alterations were identified in any case and no other evaluated gene (MAF<0.0001) had recurrent, deleterious mutations in >2 cases. The molecular genetic profiles showed no association with patient sex, age, tumoral histology or anatomic site. OncoScan SNP array analysis was performed on 10 cases and showed high concordance with the whole exome data, validating the large-scale deletions, duplications, and chr7 chromothripsis findings. In soft tissue perineuriomas, recurrent 22q12 deletions (with NF2) and 17q11 deletions (with NF1) appear to be mutually exclusive events, and alterations in NF1 or NF2 likely contribute to perineurioma pathogenesis, similar to other nerve sheath tumors. Moreover, the lack of TRAF7 mutations in soft tissue perineuriomas indicates divergent pathogenetic mechanisms from those of intraneural perineuriomas.
Abstract TP54: Machine-Learned Characterization of Acute Ischemic Stroke Clots Reveals a Correlation Between Clot Composition and Density on CT
Wang, Shunli , Murphree, Dennis H. , Douglas, Andrew , Kadirvel, Ramanathan , Brinjikji, Waleed , Kallmes, David F. , Karen, Doyle M, Fitzgerald, Seán , Dai, Daying , Pandit, Abhay

Mayo Clinic

Stroke | October 8, 2018 | Volume: 49 | Issue: Suppl_1 | Pages: No page available

10.1161/str.49.suppl_1.tp54 Get It

Introduction: The composition of acute ischemic stroke (AIS) blood clots can impact their successful removal via endovascular therapy. Identification of the clot composition prior to endovascular treatment may influence the optimal treatment strategy. In this study, we aimed to investigate the relationship between the Hounsfield Unit intensity on CT and machine-learned characterization of clot composition. Methods: Prior to endovascular treatment, each patient had a non-contrast CT performed. Histopathological analysis of the clots was performed and clot composition was quantified via standard thresholding techniques using Adobe Photoshop. In addition, following representative cell labeling by an expert pathologist, image segmentation algorithms (Orbital Image Analysis, Actelion Ltd.) were trained on each case to quantify composition by cell type. The clots were categorized into 3 groups: red blood cell (RBC) dominant (>50%), RBC proportion equal to fibrin and fibrin dominant (>50%). Correlations between clot composition and Hounsfield Units (HU) density on CT were assessed. A positive Hyperdense Artery Sign was defined as ≥50 HU. Results: Twenty patients were included in the study. There was a significant correlation between clots quantified using Adobe Photoshop Image-Pro and Orbit image analysis ( ρ = 0.837, p < 0.001). A significant relationship was found between clot composition and the presence of a HAS sign, ( X 2 (2) = 6.496, p = 0.039). There is a significant positive correlation between percentage of RBC in the clot and the presence of a HAS sign ( ρ = 0.632, p = 0.002**). There is also a significant positive correlation between the presence of fibrin-rich and the absence of a HAS sign ( ρ = 0.600, p = 0.004**). Conclusion: Machine learning software can accurately quantify AIS clot composition. The Hounsfield unit density of an AIS clot on a non-contrast CT correlates with the composition of the clot. Measuring the HU of the clot on CT prior to endovascular intervention may inform the clinician of the clot type and help to determine the most appropriate treatment strategy for that clot.
Impact of route of administration on genotoxic oestrogens concentrations using oral vs transdermal oestradiol in girls with Turner syndrome
Mauras, Nelly , Torres‐Santiago, Lournaris , Santen, Richard, Ross, Judith L. , Colón‐Otero, Gerardo , Damaso, Ligeia, Hossain, Jobayer , Wang, Qingqing , Mesaros, Clementina , Mericq, Verónica , Blair, Ian A.

Mayo Clinic

Clinical Endocrinology | October 5, 2018 | Volume: 90 | Issue: 1 | Pages: 155-161

10.1111/cen.13869 | PMID 30281805 Get It

AbstractObjectiveThe established link between oestrogen and breast cancer occurs via both oestrogen receptor (ER)‐mediated and non ER‐mediated mechanisms. The term genotoxic estrogens describes mutagenic metabolites, including oestrogen catechols and quinones, which have been linked to breast carcinogenesis in post‐menopausal women. We aimed to assess whether the route of administration of 17β oestradiol (E2) affects the accumulation of genotoxic oestrogen metabolites in a model of ovarian failure in young girls with Turner syndrome.MethodsStored plasma samples obtained at 0 and 12 months were used from 40 adolescents with Turner syndrome who participated in a 12 months randomized controlled trial of the metabolic impact of E2 orally (2 mg/d) vs transdermally (100 µg/d); dose escalation allowed matching of unconjugated E2 levels in the parent study. We measured 12 oestrogen metabolites (total concentrations = conjugated and unconjugated) using a highly sensitive LCMSMS assay. Results from 48 normally menstruating adolescents were used for comparison.ResultsAfter treatment, least square mean (SE) total E2 concentrations were higher in the oral vs transdermal group (6784 pmol/L vs 1123 [1614], P < 0.0001), as was oestrone (E1) (91 060 pmol/L vs 19 278 [16 534], P < 0.0001). Also, higher after oral treatment were catechol‐oestrogens 4‐hydroxy‐E2 (149 vs 28 [±49] pmol/L), 2‐hydroxy‐E2 (300 vs 76 [±52]), 4‐hydroxy‐E1 (450 vs 105 [±113]), 2‐hydroxy‐E1 (3094 vs 740 [±684]) and 16α‐hydroxy‐E1 (3,007 vs 157 [±534]) (<0.001 between groups). Levels were much closer to controls in the transdermal group.ConclusionsCommon feminizing doses of oral oestradiol for 12 months result in substantial accumulation of unphysiologic, genotoxic oestrogens compared to transdermal oestradiol, expanding concerns about oral oestrogens’ first hepatic passage. Further studies assessing long‐term risks of these metabolites in women taking different forms of oestrogen are needed.
Poor performance of psoas muscle index for identification of patients with higher waitlist mortality risk in cirrhosis
Wang, Connie W. , Dunn, Michael A. , Carey, Elizabeth J. , Ebadi, Maryam , Lai, Jennifer C. , Dasarathy, Srinivasan , Kappus, Matthew R. , Montaño‐Loza, Aldo J.

Mayo Clinic

Journal of Cachexia, Sarcopenia and Muscle | September 30, 2018 | Volume: 9 | Issue: 6 | Pages: 1053-1062

10.1002/jcsm.12349 | PMID 30269421 Get It

AbstractBackgroundSarcopenia, characterized by low muscle mass, associates with mortality in patients with cirrhosis. Skeletal muscle area in a single computed tomography image at the level of the third lumbar vertebrate (L3) is a valid representative of whole body muscle mass. Controversy remains regarding applicability of psoas muscle to identify patients at greater risk of mortality. We aimed to determine psoas muscle index (PMI) association with skeletal muscle index (SMI) and to evaluate the capacity of PMI to predict liver transplant waitlist mortality.MethodsWe evaluated listed adult patients with cirrhosis from 2012 to 2013 at four North American liver transplant centres. From L3 computed tomography images within 3 months of listing, we determined SMI and PMI expressed by cm2/m2. Low SMI was defined as SMI <39 cm2/m2 in women and <50 cm2/m2 in men as published by us earlier. Cut‐offs for PMI to predict mortality were established using a receiver‐operating characteristic analysis. Mortality predictors were determined using competing‐risk analysis with reported results as subdistribution hazard ratios (sHRs).ResultsOf 353 waitlist candidates, 68% were men, mean age 56 ± 9 years, and Model for End‐stage Liver Disease of 16 ± 8 points. Low SMI was present more frequently in men than women (51 vs. 36%, P = 0.02). Moderately strong correlation between SMI and PMI was observed (r > 0.7, P < 0.001). Low PMI (males < 5.1 cm2/m2; females < 4.3 cm2/m2) yielded poor and moderate concordance with low SMI in men and women, respectively (Kappa coefficient 0.31 and 0.63). SMI (39 ± 9 vs. 43 ± 7 cm2/m2; P = 0.009) and PMI (4.4 ± 1.3 vs. 5.2 ± 1.1 cm2/m2; P = 0.001) were lower in women who died and/or were delisted (compared with non‐deceased patients) whereas men who died and/or were delisted had only lower SMI (47 ± 7 vs. 51 ± 9 cm2/m2; P = 0.003), but not PMI compared with non‐deceased patients. In women, both SMI (sHR 0.94, P = 0.048) and PMI (sHR 0.58, P = 0.002) were predictors of mortality, while in men, SMI was significant (sHR 0.95, P = 0.001) and PMI showed a trend to be (sHR 0.85, P = 0.09) associated with mortality. Overall, 104 patients (29%) were misclassified between SMI and PMI categories. Using PMI cut‐offs, 66% and 28% of low SMI men and women, who have a higher risk of mortality, were incorrectly classified as low risk.ConclusionsSkeletal muscle index is a more complete and robust measurement than PMI, especially in men with cirrhosis. Low PMI identifies an incomplete subset of patients at increased risk of mortality indicated by low SMI. Given the poor performance of PMI, SMI should not be substituted by PMI.